{
  "version": "2.0",
  "last_updated": "2026-02-16",
  "description": "Centralized FDA Pre-Submission question bank with 55+ questions across 26 categories, supporting 510(k), PMA, IDE, and De Novo pathways",
  "questions": [
    {
      "id": "PRED-001",
      "category": "predicate_selection",
      "priority": 100,
      "text": "Does FDA agree that {predicate_k_numbers} ({predicate_device_names}) {is_are} an appropriate predicate device{s} for our {device_description_short}? If not, can FDA recommend alternative predicate(s)?",
      "applicable_meeting_types": ["formal", "written", "pre-ide"],
      "applicable_pathways": ["510k"],
      "required_data": ["predicates"],
      "auto_populate": true,
      "rationale": "Core SE question - FDA must confirm predicate acceptability before submission strategy finalizes",
      "fda_guidance": "The 510(k) Program: Evaluating Substantial Equivalence (2014)"
    },
    {
      "id": "PRED-002",
      "category": "predicate_selection",
      "priority": 90,
      "text": "Our proposed predicate {primary_predicate_k_number} was cleared {years_ago} years ago. Does FDA recommend we consider more recent predicates, or is this acceptable given {similarity_rationale}?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k"],
      "required_data": ["predicates", "predicate_age"],
      "triggers": ["old_predicate"],
      "auto_populate": true,
      "rationale": "Older predicates may have outdated testing expectations - FDA input prevents RTA"
    },
    {
      "id": "CLASS-001",
      "category": "classification",
      "priority": 95,
      "text": "We believe our device is appropriately classified under product code {product_code} (21 CFR {regulation_number}, Class {device_class}). Does FDA agree with this classification?",
      "applicable_meeting_types": ["formal", "written", "info", "pre-ide", "administrative"],
      "applicable_pathways": ["510k", "pma", "de_novo", "ide"],
      "required_data": ["product_code", "regulation_number", "device_class"],
      "auto_populate": true,
      "rationale": "Classification confirmation is mandatory for all Pre-Subs - ensures regulatory pathway alignment",
      "fda_guidance": "CFR Title 21, Parts 862-892"
    },
    {
      "id": "CLASS-002",
      "category": "classification",
      "priority": 85,
      "text": "Our device has characteristics that may fall under multiple product codes ({product_codes_list}). Which product code does FDA recommend for classification?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["multi_product_code"],
      "required_data": ["product_codes_list"],
      "auto_populate": true,
      "rationale": "Product code ambiguity can delay review - early FDA determination prevents submission errors"
    },
    {
      "id": "TEST-BIO-001",
      "category": "testing_biocompatibility",
      "priority": 80,
      "text": "We propose biocompatibility testing per ISO 10993-1:2018 for {contact_type} contact with {contact_duration} duration. Does FDA agree this testing strategy is sufficient, or does FDA recommend additional endpoints?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo", "ide"],
      "triggers": ["patient_contacting"],
      "required_data": ["contact_type", "contact_duration"],
      "auto_populate": true,
      "rationale": "Biocompatibility is critical safety concern for patient-contacting devices - FDA input reduces RTA risk",
      "fda_guidance": "Use of ISO 10993-1 (2016)"
    },
    {
      "id": "TEST-BIO-002",
      "category": "testing_biocompatibility",
      "priority": 75,
      "text": "Our device uses {materials_list}. Based on predicate precedent, we propose the following ISO 10993-1 endpoints: {proposed_endpoints}. Does FDA agree, or does FDA recommend additional testing?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["patient_contacting", "novel_materials"],
      "required_data": ["materials_list", "proposed_endpoints"],
      "auto_populate": true,
      "rationale": "Novel materials require comprehensive biocompatibility characterization - endpoint selection is critical"
    },
    {
      "id": "TEST-STER-001",
      "category": "testing_sterilization",
      "priority": 80,
      "text": "We propose sterilization validation per {sterilization_standard} using {sterilization_method}. Does FDA agree this approach is sufficient?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["sterile_device"],
      "required_data": ["sterilization_method", "sterilization_standard"],
      "auto_populate": true,
      "rationale": "Sterilization validation is critical for sterile devices - FDA must confirm method appropriateness",
      "fda_guidance": "Submission and Review of Sterility Information (2019)"
    },
    {
      "id": "TEST-SHELF-001",
      "category": "testing_shelf_life",
      "priority": 70,
      "text": "We propose a {shelf_life_years}-year shelf life supported by accelerated aging per ASTM F1980. Does FDA agree with this shelf life claim and testing approach?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["sterile_device", "shelf_life_claim"],
      "required_data": ["shelf_life_years"],
      "auto_populate": true,
      "rationale": "Shelf life claims require robust validation - FDA input on accelerated aging protocols prevents rejection"
    },
    {
      "id": "TEST-PERF-001",
      "category": "testing_performance",
      "priority": 75,
      "text": "We propose the following performance testing: {performance_tests_list}. Does FDA agree this testing adequately demonstrates device performance, or does FDA recommend additional tests?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "required_data": ["performance_tests_list"],
      "auto_populate": false,
      "rationale": "Performance testing expectations vary by device type - FDA alignment prevents costly re-testing"
    },
    {
      "id": "TEST-ELEC-001",
      "category": "testing_electrical",
      "priority": 80,
      "text": "We propose electrical safety testing per IEC 60601-1 and EMC testing per IEC 60601-1-2. Does FDA agree this approach is sufficient for our {device_type}?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["powered_device"],
      "required_data": ["device_type"],
      "auto_populate": true,
      "rationale": "Electrical safety is critical for powered devices - IEC 60601 series compliance is typically expected",
      "fda_guidance": "Recognition of IEC 60601-1:2005 (Third Edition)"
    },
    {
      "id": "TEST-SOFTWARE-001",
      "category": "testing_software",
      "priority": 85,
      "text": "Our device includes software with documentation level {software_level}. We propose software validation per IEC 62304 and usability engineering per IEC 62366-1. Does FDA agree this approach is sufficient?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["software_device"],
      "required_data": ["software_level"],
      "auto_populate": true,
      "rationale": "Software validation requirements are complex - early FDA alignment on documentation level prevents deficiencies",
      "fda_guidance": "Content of Premarket Submissions for Device Software Functions (2023)"
    },
    {
      "id": "TEST-CYBER-001",
      "category": "testing_cybersecurity",
      "priority": 80,
      "text": "Our device has {connectivity_type} connectivity. We propose cybersecurity validation per FDA's 2023 guidance. Does FDA agree with this approach, or does FDA recommend additional cybersecurity measures?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["connected_device"],
      "required_data": ["connectivity_type"],
      "auto_populate": true,
      "rationale": "Cybersecurity is mandatory for connected devices - FDA guidance (2023) requires specific documentation",
      "fda_guidance": "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (2023)"
    },
    {
      "id": "TEST-HF-001",
      "category": "testing_human_factors",
      "priority": 75,
      "text": "We propose human factors validation per IEC 62366-1 with {hf_study_type}. Does FDA agree this approach adequately addresses use-related risks identified in our risk analysis?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["complex_ui", "home_use"],
      "required_data": ["hf_study_type"],
      "auto_populate": false,
      "rationale": "Human factors is critical for devices with complex UI or home use - study design must address use errors",
      "fda_guidance": "Applying Human Factors and Usability Engineering to Medical Devices (2016)"
    },
    {
      "id": "CLINICAL-001",
      "category": "clinical_evidence",
      "priority": 85,
      "text": "Based on predicate precedent showing {clinical_precedent_summary}, does FDA expect clinical data for our submission? If so, what study design would FDA recommend?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "required_data": ["clinical_precedent_summary"],
      "auto_populate": false,
      "rationale": "Clinical data expectations vary widely by device type - FDA clarity prevents wasted resources",
      "fda_guidance": "Clinical Evidence for Clearance or Approval of Medical Devices (2022)"
    },
    {
      "id": "CLINICAL-002",
      "category": "clinical_evidence",
      "priority": 80,
      "text": "We propose to support our submission with clinical data from {clinical_data_source}. Does FDA consider this sufficient, or does FDA recommend a prospective clinical study?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["clinical_question"],
      "required_data": ["clinical_data_source"],
      "auto_populate": false,
      "rationale": "Prospective vs retrospective clinical evidence has different regulatory weight - FDA input is critical"
    },
    {
      "id": "CLINICAL-STUDY-001",
      "category": "clinical_study_design",
      "priority": 90,
      "text": "We propose a clinical study with the following design: {study_design_summary}. Does FDA agree with this approach, or does FDA recommend modifications to the study protocol?",
      "applicable_meeting_types": ["pre-ide"],
      "applicable_pathways": ["pma", "ide"],
      "triggers": ["clinical_study_planned"],
      "required_data": ["study_design_summary"],
      "auto_populate": false,
      "rationale": "Clinical study protocol must be aligned with FDA expectations before initiation - prevents study failures"
    },
    {
      "id": "ENDPOINTS-001",
      "category": "clinical_study_design",
      "priority": 85,
      "text": "We propose the following primary endpoint: {primary_endpoint}. Does FDA agree this endpoint adequately demonstrates device safety and effectiveness?",
      "applicable_meeting_types": ["pre-ide"],
      "applicable_pathways": ["pma", "ide"],
      "triggers": ["clinical_study_planned"],
      "required_data": ["primary_endpoint"],
      "auto_populate": false,
      "rationale": "Primary endpoint selection is critical for study success - FDA must confirm clinical relevance"
    },
    {
      "id": "IRB-001",
      "category": "clinical_study_design",
      "priority": 75,
      "text": "Do FDA and our IRB consider this device to be a significant risk (SR) or non-significant risk (NSR) device for the purposes of the proposed clinical study?",
      "applicable_meeting_types": ["pre-ide"],
      "applicable_pathways": ["ide"],
      "triggers": ["clinical_study_planned"],
      "auto_populate": false,
      "rationale": "SR vs NSR determination affects IDE requirements - early FDA determination streamlines study initiation",
      "fda_guidance": "Significant Risk and Nonsignificant Risk Medical Device Studies (2006)"
    },
    {
      "id": "NOVEL-001",
      "category": "novel_technology",
      "priority": 90,
      "text": "Our device includes {novel_feature_description} not present in the proposed predicate. What additional data, if any, does FDA recommend to address this design difference?",
      "applicable_meeting_types": ["formal"],
      "applicable_pathways": ["510k"],
      "triggers": ["novel_features"],
      "required_data": ["novel_feature_description"],
      "auto_populate": false,
      "rationale": "Novel features are primary SE barrier - early FDA input prevents costly testing mistakes",
      "fda_guidance": "The 510(k) Program: Evaluating Substantial Equivalence (2014), Section VI"
    },
    {
      "id": "NOVEL-002",
      "category": "novel_technology",
      "priority": 85,
      "text": "Given the novel {technology_aspect}, does FDA agree the 510(k) pathway remains appropriate, or should we consider the De Novo pathway?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["510k", "de_novo"],
      "triggers": ["novel_features", "pathway_uncertainty"],
      "required_data": ["technology_aspect"],
      "auto_populate": false,
      "rationale": "Pathway determination is critical early decision - incorrect pathway wastes significant time and resources"
    },
    {
      "id": "IFU-001",
      "category": "indications_for_use",
      "priority": 80,
      "text": "Our proposed indications for use extend beyond the predicate to include {ifu_extension}. Does FDA consider this within the scope of substantial equivalence, or does FDA recommend narrowing the indications?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k"],
      "triggers": ["ifu_extension"],
      "required_data": ["ifu_extension"],
      "auto_populate": false,
      "rationale": "IFU scope directly impacts SE determination - FDA must confirm acceptability of extensions"
    },
    {
      "id": "IFU-002",
      "category": "indications_for_use",
      "priority": 75,
      "text": "Does FDA agree our proposed indications for use ({proposed_ifu_summary}) are appropriately specific for a Class {device_class} device?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "required_data": ["proposed_ifu_summary", "device_class"],
      "auto_populate": true,
      "rationale": "IFU specificity requirements vary by device class - FDA input ensures regulatory alignment"
    },
    {
      "id": "LABEL-001",
      "category": "labeling",
      "priority": 70,
      "text": "Based on predicate labeling precedent, we propose the following key labeling elements: {labeling_elements}. Does FDA agree this labeling is adequate?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "required_data": ["labeling_elements"],
      "auto_populate": false,
      "rationale": "Labeling deficiencies are common RTA reason - early FDA review prevents rejection"
    },
    {
      "id": "LABEL-002",
      "category": "labeling",
      "priority": 65,
      "text": "Our device will include the following warnings and precautions: {warnings_list}. Does FDA recommend additional warnings based on the device risk profile?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "required_data": ["warnings_list"],
      "auto_populate": false,
      "rationale": "Warning adequacy is critical for risk mitigation - FDA input ensures comprehensive risk communication"
    },
    {
      "id": "MFG-001",
      "category": "manufacturing",
      "priority": 60,
      "text": "Our device will be manufactured at {manufacturing_location}. Does FDA foresee any regulatory concerns with this manufacturing location?",
      "applicable_meeting_types": ["formal", "written", "info"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "required_data": ["manufacturing_location"],
      "auto_populate": false,
      "rationale": "Manufacturing location can impact review timeline - early disclosure identifies potential issues"
    },
    {
      "id": "MFG-002",
      "category": "manufacturing",
      "priority": 55,
      "text": "We propose to make the following manufacturing changes compared to the predicate: {manufacturing_changes}. Does FDA consider these changes to impact substantial equivalence?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k"],
      "triggers": ["manufacturing_difference"],
      "required_data": ["manufacturing_changes"],
      "auto_populate": false,
      "rationale": "Manufacturing changes can raise SE concerns - FDA input clarifies if validation data is needed"
    },
    {
      "id": "PATHWAY-001",
      "category": "regulatory_pathway",
      "priority": 95,
      "text": "Based on our analysis, we believe the {proposed_pathway} pathway is appropriate for this device. Does FDA agree, or does FDA recommend an alternative pathway?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["510k", "pma", "de_novo", "ide"],
      "required_data": ["proposed_pathway"],
      "auto_populate": true,
      "rationale": "Pathway confirmation is fundamental decision - incorrect pathway wastes months of effort",
      "fda_guidance": "Is a 510(k) Required? (2019)"
    },
    {
      "id": "PATHWAY-002",
      "category": "regulatory_pathway",
      "priority": 85,
      "text": "Given the absence of {missing_element}, are there any special considerations or additional data FDA would recommend to support the {proposed_pathway} pathway?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["pathway_uncertainty"],
      "required_data": ["missing_element", "proposed_pathway"],
      "auto_populate": false,
      "rationale": "Pathway gaps (e.g., no clear predicate) require strategic FDA alignment"
    },
    {
      "id": "PATHWAY-003",
      "category": "regulatory_pathway",
      "priority": 80,
      "text": "We are considering both the 510(k) and De Novo pathways for this device. What factors should we prioritize in making this strategic decision?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["510k", "de_novo"],
      "triggers": ["pathway_uncertainty"],
      "auto_populate": false,
      "rationale": "Strategic pathway selection requires FDA input when both options are viable"
    },
    {
      "id": "REPROCESS-001",
      "category": "reprocessing",
      "priority": 75,
      "text": "Our device is reusable and will be reprocessed {reprocessing_cycles} times. We propose reprocessing validation per {reprocessing_standard}. Does FDA agree this approach is sufficient?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["reusable_device"],
      "required_data": ["reprocessing_cycles", "reprocessing_standard"],
      "auto_populate": true,
      "rationale": "Reprocessing validation is critical for reusable devices - FDA guidance requires specific documentation",
      "fda_guidance": "Reprocessing Medical Devices in Health Care Settings (2015)"
    },
    {
      "id": "COMBO-001",
      "category": "combination_product",
      "priority": 85,
      "text": "Our device includes a {drug_component} component. We believe the device is the primary mode of action. Does FDA agree with this classification, or should we pursue a combination product designation?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["combination_product"],
      "required_data": ["drug_component"],
      "auto_populate": false,
      "rationale": "Combination product designation determines lead center (CDRH vs CDER) - early determination is critical",
      "fda_guidance": "Classification of Products as Drugs and Devices (2018)"
    },
    {
      "id": "STANDARDS-001",
      "category": "consensus_standards",
      "priority": 70,
      "text": "We propose to use the following FDA-recognized consensus standards: {standards_list}. Does FDA agree these standards adequately address the device-specific risks?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "required_data": ["standards_list"],
      "auto_populate": true,
      "rationale": "Standards selection must map to device risks - FDA confirmation ensures comprehensive testing coverage"
    },
    {
      "id": "TIMELINE-001",
      "category": "administrative",
      "priority": 50,
      "text": "We are planning to submit our {submission_type_name} in {submission_timeline}. Are there any known review delays or backlogs for {product_code} devices that we should consider in our timeline planning?",
      "applicable_meeting_types": ["info", "administrative"],
      "applicable_pathways": ["510k", "pma", "de_novo", "ide"],
      "required_data": ["submission_timeline", "product_code"],
      "auto_populate": true,
      "rationale": "Review timeline awareness supports strategic planning - FDA transparency on backlogs is valuable"
    },
    {
      "id": "PRIOR-INTERACTION-001",
      "category": "administrative",
      "priority": 60,
      "text": "We previously submitted {prior_submission_type} for a related device ({prior_k_number}). Are there any carryover considerations or lessons learned from that submission that FDA recommends we address?",
      "applicable_meeting_types": ["formal", "info"],
      "applicable_pathways": ["510k", "pma", "de_novo"],
      "triggers": ["prior_submissions"],
      "required_data": ["prior_submission_type", "prior_k_number"],
      "auto_populate": false,
      "rationale": "Prior submission history can impact review approach - FDA input on carryover issues is valuable"
    },
    {
      "id": "PMA-CLINICAL-001",
      "category": "pma_clinical",
      "priority": 95,
      "text": "We propose a pivotal clinical study with {study_design_summary} to support PMA approval. Does FDA agree this study design is adequate to demonstrate reasonable assurance of safety and effectiveness?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["pma"],
      "triggers": ["pma_pathway"],
      "required_data": ["study_design_summary"],
      "auto_populate": false,
      "rationale": "PMA pivotal study design must be aligned with FDA expectations - misalignment can waste years and millions of dollars",
      "fda_guidance": "Design Considerations for Pivotal Clinical Investigations for Medical Devices (2013)"
    },
    {
      "id": "PMA-CLINICAL-002",
      "category": "pma_clinical",
      "priority": 90,
      "text": "We propose {primary_endpoint} as our primary effectiveness endpoint with a success criterion of {success_criterion}. Does FDA agree this endpoint and criterion are clinically meaningful and statistically appropriate?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["pma"],
      "triggers": ["pma_pathway"],
      "required_data": ["primary_endpoint", "success_criterion"],
      "auto_populate": false,
      "rationale": "Primary endpoint selection is the most critical PMA design decision - FDA must confirm acceptability before study begins"
    },
    {
      "id": "PMA-CLINICAL-003",
      "category": "pma_clinical",
      "priority": 85,
      "text": "Our statistical analysis plan uses {statistical_approach} with sample size of {sample_size} (power: {power_level}, alpha: {alpha_level}). Does FDA agree with this approach, including the assumptions for effect size and dropout rate?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["pma"],
      "triggers": ["pma_pathway"],
      "required_data": ["statistical_approach", "sample_size"],
      "auto_populate": false,
      "rationale": "Underpowered studies are a major PMA failure mode - FDA must validate statistical assumptions before enrollment"
    },
    {
      "id": "PMA-RISK-001",
      "category": "pma_risk_assessment",
      "priority": 80,
      "text": "Our benefit-risk analysis indicates {benefit_risk_summary}. Does FDA agree that the anticipated benefits outweigh the risks for the intended patient population?",
      "applicable_meeting_types": ["formal"],
      "applicable_pathways": ["pma"],
      "triggers": ["pma_pathway"],
      "required_data": ["benefit_risk_summary"],
      "auto_populate": false,
      "rationale": "PMA approval requires positive benefit-risk balance - FDA alignment on assessment methodology is essential",
      "fda_guidance": "Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions (2017)"
    },
    {
      "id": "PMA-NONCLIN-001",
      "category": "pma_nonclinical",
      "priority": 75,
      "text": "We have completed the following nonclinical testing: {nonclinical_testing_summary}. Does FDA agree this nonclinical evidence is sufficient to support initiation of a pivotal clinical study, or does FDA recommend additional bench or animal testing?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["pma"],
      "triggers": ["pma_pathway"],
      "required_data": ["nonclinical_testing_summary"],
      "auto_populate": false,
      "rationale": "Nonclinical evidence supports IDE application and study safety - FDA must confirm adequacy before clinical enrollment"
    },
    {
      "id": "PMA-PANEL-001",
      "category": "pma_advisory_panel",
      "priority": 70,
      "text": "Does FDA anticipate that our PMA will be referred to an advisory committee panel for review? If so, what additional information should we prepare for the panel meeting?",
      "applicable_meeting_types": ["formal"],
      "applicable_pathways": ["pma"],
      "triggers": ["pma_pathway"],
      "auto_populate": false,
      "rationale": "Advisory panel referral adds months to review - early awareness enables preparation of panel presentations"
    },
    {
      "id": "IDE-SR-NSR-001",
      "category": "ide_risk_determination",
      "priority": 95,
      "text": "Based on our risk analysis, we have determined this device presents {risk_level} risk per 21 CFR 812.3(m). Does FDA agree with our SR/NSR determination? Our rationale: {sr_nsr_rationale}.",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["ide"],
      "triggers": ["ide_pathway"],
      "required_data": ["risk_level", "sr_nsr_rationale"],
      "auto_populate": false,
      "rationale": "SR vs NSR determination dictates IDE vs abbreviated IDE requirements - FDA confirmation prevents wasted effort",
      "fda_guidance": "Significant Risk and Nonsignificant Risk Medical Device Studies (2006)"
    },
    {
      "id": "IDE-PROTOCOL-001",
      "category": "ide_study_protocol",
      "priority": 90,
      "text": "We propose a {study_type} clinical investigation at {number_of_sites} site(s) with {sample_size} subjects. Does FDA agree with our proposed protocol, or does FDA recommend modifications?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["ide"],
      "triggers": ["ide_pathway"],
      "required_data": ["study_type", "number_of_sites", "sample_size"],
      "auto_populate": false,
      "rationale": "IDE protocol must satisfy 21 CFR 812.25 requirements - early FDA alignment prevents study delays"
    },
    {
      "id": "IDE-CONSENT-001",
      "category": "ide_informed_consent",
      "priority": 75,
      "text": "We have prepared informed consent documents per 21 CFR 50. Does FDA have specific recommendations for the informed consent content given the device's risk profile?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["ide"],
      "triggers": ["ide_pathway"],
      "auto_populate": false,
      "rationale": "Inadequate informed consent can halt clinical studies - FDA input prevents IRB rejection or study suspension",
      "fda_guidance": "Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors (1998)"
    },
    {
      "id": "IDE-MONITOR-001",
      "category": "ide_study_monitoring",
      "priority": 70,
      "text": "Our monitoring plan includes {monitoring_approach}. Does FDA recommend a Data Safety Monitoring Board (DSMB) for this investigation, and does FDA have recommendations for our interim analysis plan?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["ide"],
      "triggers": ["ide_pathway"],
      "required_data": ["monitoring_approach"],
      "auto_populate": false,
      "rationale": "Safety monitoring plan must be adequate for device risk - FDA may mandate DSMB or specific stopping rules"
    },
    {
      "id": "IDE-FEASIBILITY-001",
      "category": "ide_feasibility",
      "priority": 80,
      "text": "We are proposing an early feasibility study per FDA guidance with {feasibility_design}. Does FDA agree this early feasibility design is appropriate before a pivotal study, and what criteria should define transition to pivotal?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["ide"],
      "triggers": ["ide_pathway", "early_feasibility"],
      "required_data": ["feasibility_design"],
      "auto_populate": false,
      "rationale": "Early feasibility studies have different requirements than pivotal studies - FDA must confirm scope and transition criteria",
      "fda_guidance": "Investigational Device Exemptions (IDE) for Early Feasibility Medical Device Clinical Studies (2013)"
    },
    {
      "id": "DENOVO-RISK-001",
      "category": "de_novo_risk",
      "priority": 95,
      "text": "We believe our device qualifies for De Novo classification as a low-to-moderate risk device. Our risk assessment identifies the following key risks: {risk_summary}. Does FDA agree with our risk classification?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["de_novo"],
      "triggers": ["de_novo_pathway"],
      "required_data": ["risk_summary"],
      "auto_populate": false,
      "rationale": "De Novo requires demonstration of low-to-moderate risk - FDA must agree before investment in special controls",
      "fda_guidance": "De Novo Classification Process (Evaluation of Automatic Class III Designation) (2021)"
    },
    {
      "id": "DENOVO-CONTROLS-001",
      "category": "de_novo_special_controls",
      "priority": 90,
      "text": "We propose the following special controls for our device: {proposed_special_controls}. Does FDA agree these controls are adequate to provide reasonable assurance of safety and effectiveness?",
      "applicable_meeting_types": ["formal"],
      "applicable_pathways": ["de_novo"],
      "triggers": ["de_novo_pathway"],
      "required_data": ["proposed_special_controls"],
      "auto_populate": false,
      "rationale": "Special controls are the core of De Novo classification - FDA must confirm adequacy before full submission investment"
    },
    {
      "id": "DENOVO-PREDICATE-001",
      "category": "de_novo_predicate_search",
      "priority": 85,
      "text": "Our search for legally marketed predicate devices identified {predicate_search_results}. Does FDA agree that no appropriate predicate exists, supporting the De Novo pathway?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["de_novo"],
      "triggers": ["de_novo_pathway"],
      "required_data": ["predicate_search_results"],
      "auto_populate": false,
      "rationale": "No-predicate justification is foundational to De Novo - FDA must confirm the absence before full classification request"
    },
    {
      "id": "DENOVO-CLASSIFICATION-001",
      "category": "de_novo_classification",
      "priority": 80,
      "text": "We propose our device be classified into product code {proposed_product_code} under 21 CFR {proposed_regulation}. If this is a new device type, what product code and regulation number does FDA anticipate assigning?",
      "applicable_meeting_types": ["formal", "administrative"],
      "applicable_pathways": ["de_novo"],
      "triggers": ["de_novo_pathway"],
      "required_data": ["proposed_product_code"],
      "auto_populate": false,
      "rationale": "De Novo classification creates new regulatory classification - FDA input on product code is essential for submission planning"
    },
    {
      "id": "DENOVO-CLINICAL-001",
      "category": "de_novo_clinical",
      "priority": 75,
      "text": "We propose to support our De Novo request with {clinical_evidence_type}. Does FDA agree this clinical evidence is sufficient, or does FDA require additional clinical data to support the proposed special controls?",
      "applicable_meeting_types": ["formal", "pre-ide"],
      "applicable_pathways": ["de_novo"],
      "triggers": ["de_novo_pathway"],
      "required_data": ["clinical_evidence_type"],
      "auto_populate": false,
      "rationale": "Clinical evidence requirements for De Novo vary widely - FDA alignment prevents submission rejection"
    },
    {
      "id": "DENOVO-LABELING-001",
      "category": "de_novo_labeling",
      "priority": 70,
      "text": "Our proposed labeling includes the following special controls-related information: {labeling_controls}. Does FDA agree this labeling adequately implements the proposed special controls?",
      "applicable_meeting_types": ["formal", "written"],
      "applicable_pathways": ["de_novo"],
      "triggers": ["de_novo_pathway"],
      "required_data": ["labeling_controls"],
      "auto_populate": false,
      "rationale": "Labeling is a primary mechanism for implementing special controls - FDA must confirm adequacy"
    }
  ],
  "meeting_type_defaults": {
    "formal": ["PRED-001", "CLASS-001", "TEST-BIO-001", "TEST-PERF-001", "NOVEL-001", "IFU-001", "PATHWAY-001"],
    "written": ["PRED-001", "CLASS-001", "TEST-BIO-001", "IFU-001"],
    "info": ["CLASS-001", "MFG-001"],
    "pre-ide": ["CLASS-001", "CLINICAL-STUDY-001", "ENDPOINTS-001", "IRB-001"],
    "administrative": ["CLASS-001", "PATHWAY-001", "PATHWAY-003"],
    "info-only": []
  },
  "pathway_defaults": {
    "510k": ["PRED-001", "CLASS-001", "PATHWAY-001"],
    "pma": ["CLASS-001", "PMA-CLINICAL-001", "PMA-CLINICAL-002", "PMA-RISK-001", "PMA-NONCLIN-001", "PATHWAY-001"],
    "ide": ["CLASS-001", "IDE-SR-NSR-001", "IDE-PROTOCOL-001", "ENDPOINTS-001", "IDE-CONSENT-001", "PATHWAY-001"],
    "de_novo": ["CLASS-001", "DENOVO-RISK-001", "DENOVO-CONTROLS-001", "DENOVO-PREDICATE-001", "PATHWAY-001"]
  },
  "auto_triggers": {
    "patient_contacting": ["TEST-BIO-001", "TEST-BIO-002"],
    "sterile_device": ["TEST-STER-001", "TEST-SHELF-001"],
    "powered_device": ["TEST-ELEC-001"],
    "software_device": ["TEST-SOFTWARE-001"],
    "connected_device": ["TEST-CYBER-001"],
    "novel_features": ["NOVEL-001", "NOVEL-002"],
    "clinical_study_planned": ["CLINICAL-STUDY-001", "ENDPOINTS-001", "IRB-001"],
    "ifu_extension": ["IFU-001"],
    "pathway_uncertainty": ["PATHWAY-002", "PATHWAY-003"],
    "reusable_device": ["REPROCESS-001"],
    "combination_product": ["COMBO-001"],
    "complex_ui": ["TEST-HF-001"],
    "home_use": ["TEST-HF-001"],
    "pma_pathway": ["PMA-CLINICAL-001", "PMA-CLINICAL-002", "PMA-RISK-001", "PMA-NONCLIN-001"],
    "ide_pathway": ["IDE-SR-NSR-001", "IDE-PROTOCOL-001", "IDE-CONSENT-001", "IDE-MONITOR-001"],
    "de_novo_pathway": ["DENOVO-RISK-001", "DENOVO-CONTROLS-001", "DENOVO-PREDICATE-001", "DENOVO-CLASSIFICATION-001"],
    "early_feasibility": ["IDE-FEASIBILITY-001"]
  },
  "categories": {
    "predicate_selection": "Questions about predicate device selection and acceptability",
    "classification": "Questions about device classification and product code",
    "testing_biocompatibility": "Biocompatibility testing strategy and ISO 10993 compliance",
    "testing_sterilization": "Sterilization validation and shelf life",
    "testing_shelf_life": "Shelf life claims and accelerated aging",
    "testing_performance": "Performance testing and functional validation",
    "testing_electrical": "Electrical safety and EMC testing (IEC 60601 series)",
    "testing_software": "Software validation and cybersecurity (IEC 62304, IEC 62366)",
    "testing_cybersecurity": "Cybersecurity for connected devices",
    "testing_human_factors": "Human factors and usability engineering",
    "clinical_evidence": "Clinical data requirements and study design",
    "clinical_study_design": "Clinical study protocol, endpoints, and IRB considerations",
    "novel_technology": "Novel features and technological characteristics",
    "indications_for_use": "IFU scope and specificity",
    "labeling": "Labeling content, warnings, and precautions",
    "manufacturing": "Manufacturing location and process changes",
    "regulatory_pathway": "Pathway selection (510k, De Novo, PMA, IDE)",
    "reprocessing": "Reprocessing validation for reusable devices",
    "combination_product": "Drug-device combination products",
    "consensus_standards": "FDA-recognized consensus standards selection",
    "administrative": "Administrative questions (timeline, prior interactions)",
    "pma_clinical": "PMA-specific clinical study design, endpoints, and statistical planning",
    "pma_risk_assessment": "PMA benefit-risk analysis and regulatory assessment",
    "pma_nonclinical": "PMA nonclinical testing requirements and sufficiency",
    "pma_advisory_panel": "PMA advisory committee panel review considerations",
    "ide_risk_determination": "IDE significant risk vs non-significant risk determination (21 CFR 812)",
    "ide_study_protocol": "IDE clinical study protocol design (21 CFR 812.25)",
    "ide_informed_consent": "IDE informed consent requirements (21 CFR 50)",
    "ide_study_monitoring": "IDE safety monitoring, DSMB, and stopping rules",
    "ide_feasibility": "IDE early feasibility study design and transition criteria",
    "de_novo_risk": "De Novo risk assessment and classification justification",
    "de_novo_special_controls": "De Novo proposed special controls development",
    "de_novo_predicate_search": "De Novo no-predicate justification and search documentation",
    "de_novo_classification": "De Novo product code and regulation assignment",
    "de_novo_clinical": "De Novo clinical evidence requirements",
    "de_novo_labeling": "De Novo special controls implementation through labeling"
  }
}
